BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 36560719)

  • 1. The Optimized γ-Globin Lentiviral Vector GGHI-mB-3D Leads to Nearly Therapeutic HbF Levels In Vitro in CD34
    Drakopoulou E; Georgomanoli M; Lederer CW; Panetsos F; Kleanthous M; Voskaridou E; Valakos D; Papanikolaou E; Anagnou NP
    Viruses; 2022 Dec; 14(12):. PubMed ID: 36560719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel BaEVRless-Pseudotyped γ-Globin Lentiviral Vector Drives High and Stable Fetal Hemoglobin Expression and Improves Thalassemic Erythropoiesis
    Drakopoulou E; Georgomanoli M; Lederer CW; Kleanthous M; Costa C; Bernadin O; Cosset FL; Voskaridou E; Verhoeyen E; Papanikolaou E; Anagnou NP
    Hum Gene Ther; 2019 May; 30(5):601-617. PubMed ID: 30324804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The new self-inactivating lentiviral vector for thalassemia gene therapy combining two HPFH activating elements corrects human thalassemic hematopoietic stem cells.
    Papanikolaou E; Georgomanoli M; Stamateris E; Panetsos F; Karagiorga M; Tsaftaridis P; Graphakos S; Anagnou NP
    Hum Gene Ther; 2012 Jan; 23(1):15-31. PubMed ID: 21875313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin.
    Pestina TI; Hargrove PW; Jay D; Gray JT; Boyd KM; Persons DA
    Mol Ther; 2009 Feb; 17(2):245-52. PubMed ID: 19050697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic levels of fetal hemoglobin in erythroid progeny of β-thalassemic CD34+ cells after lentiviral vector-mediated gene transfer.
    Wilber A; Hargrove PW; Kim YS; Riberdy JM; Sankaran VG; Papanikolaou E; Georgomanoli M; Anagnou NP; Orkin SH; Nienhuis AW; Persons DA
    Blood; 2011 Mar; 117(10):2817-26. PubMed ID: 21156846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lentiviral Transfer of γ-Globin with Fusion Gene NUP98-HOXA10HD Expands Hematopoietic Stem Cells and Ameliorates Murine β-Thalassemia.
    Zhao HF; Abraham A; Kim YS; Wang YD; Pestina T; Zhan J; Humphries K; Nienhuis AW; Persons DA
    Mol Ther; 2017 Mar; 25(3):593-605. PubMed ID: 28190779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic hemoglobin levels after gene transfer in β-thalassemia mice and in hematopoietic cells of β-thalassemia and sickle cells disease patients.
    Breda L; Casu C; Gardenghi S; Bianchi N; Cartegni L; Narla M; Yazdanbakhsh K; Musso M; Manwani D; Little J; Gardner LB; Kleinert DA; Prus E; Fibach E; Grady RW; Giardina PJ; Gambari R; Rivella S
    PLoS One; 2012; 7(3):e32345. PubMed ID: 22479321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentially therapeutic levels of anti-sickling globin gene expression following lentivirus-mediated gene transfer in sickle cell disease bone marrow CD34+ cells.
    Urbinati F; Hargrove PW; Geiger S; Romero Z; Wherley J; Kaufman ML; Hollis RP; Chambers CB; Persons DA; Kohn DB; Wilber A
    Exp Hematol; 2015 May; 43(5):346-351. PubMed ID: 25681747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The degree of phenotypic correction of murine beta -thalassemia intermedia following lentiviral-mediated transfer of a human gamma-globin gene is influenced by chromosomal position effects and vector copy number.
    Persons DA; Hargrove PW; Allay ER; Hanawa H; Nienhuis AW
    Blood; 2003 Mar; 101(6):2175-83. PubMed ID: 12411297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene Therapy for Sickle Cell Disease: A Lentiviral Vector Comparison Study.
    Urbinati F; Campo Fernandez B; Masiuk KE; Poletti V; Hollis RP; Koziol C; Kaufman ML; Brown D; Mavilio F; Kohn DB
    Hum Gene Ther; 2018 Oct; 29(10):1153-1166. PubMed ID: 30198339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition.
    Traxler EA; Yao Y; Wang YD; Woodard KJ; Kurita R; Nakamura Y; Hughes JR; Hardison RC; Blobel GA; Li C; Weiss MJ
    Nat Med; 2016 Sep; 22(9):987-90. PubMed ID: 27525524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended beta-globin locus control region elements promote consistent therapeutic expression of a gamma-globin lentiviral vector in murine beta-thalassemia.
    Hanawa H; Hargrove PW; Kepes S; Srivastava DK; Nienhuis AW; Persons DA
    Blood; 2004 Oct; 104(8):2281-90. PubMed ID: 15198957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies.
    Magrin E; Miccio A; Cavazzana M
    Blood; 2019 Oct; 134(15):1203-1213. PubMed ID: 31467062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced HbF reactivation by multiplex mutagenesis of thalassemic CD34+ cells in vitro and in vivo.
    Psatha N; Georgakopoulou A; Li C; Nandakumar V; Georgolopoulos G; Acosta R; Paschoudi K; Nelson J; Chee D; Athanasiadou A; Kouvatsi A; Funnell APW; Lieber A; Yannaki E; Papayannopoulou T
    Blood; 2021 Oct; 138(17):1540-1553. PubMed ID: 34086867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amelioration of murine beta-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both gamma-globin and the MGMT drug-resistance gene.
    Zhao H; Pestina TI; Nasimuzzaman M; Mehta P; Hargrove PW; Persons DA
    Blood; 2009 Jun; 113(23):5747-56. PubMed ID: 19365082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel HPFH-like mutations by CRISPR base editing that elevate the expression of fetal hemoglobin.
    Ravi NS; Wienert B; Wyman SK; Bell HW; George A; Mahalingam G; Vu JT; Prasad K; Bandlamudi BP; Devaraju N; Rajendiran V; Syedbasha N; Pai AA; Nakamura Y; Kurita R; Narayanasamy M; Balasubramanian P; Thangavel S; Marepally S; Velayudhan SR; Srivastava A; DeWitt MA; Crossley M; Corn JE; Mohankumar KM
    Elife; 2022 Feb; 11():. PubMed ID: 35147495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis of lentiviral gene transfer approaches designed to promote fetal hemoglobin production for the treatment of β-hemoglobinopathies.
    Daniel-Moreno A; Lamsfus-Calle A; Wilber A; Chambers CB; Johnston I; Antony JS; Epting T; Handgretinger R; Mezger M
    Blood Cells Mol Dis; 2020 Sep; 84():102456. PubMed ID: 32498026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A zinc-finger transcriptional activator designed to interact with the gamma-globin gene promoters enhances fetal hemoglobin production in primary human adult erythroblasts.
    Wilber A; Tschulena U; Hargrove PW; Kim YS; Persons DA; Barbas CF; Nienhuis AW
    Blood; 2010 Apr; 115(15):3033-41. PubMed ID: 20190190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly efficient therapeutic gene editing of human hematopoietic stem cells.
    Wu Y; Zeng J; Roscoe BP; Liu P; Yao Q; Lazzarotto CR; Clement K; Cole MA; Luk K; Baricordi C; Shen AH; Ren C; Esrick EB; Manis JP; Dorfman DM; Williams DA; Biffi A; Brugnara C; Biasco L; Brendel C; Pinello L; Tsai SQ; Wolfe SA; Bauer DE
    Nat Med; 2019 May; 25(5):776-783. PubMed ID: 30911135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of lentiviral and genome editing technologies for the treatment of sickle cell disease.
    Ramadier S; Chalumeau A; Felix T; Othman N; Aknoun S; Casini A; Maule G; Masson C; De Cian A; Frati G; Brusson M; Concordet JP; Cavazzana M; Cereseto A; El Nemer W; Amendola M; Wattellier B; Meneghini V; Miccio A
    Mol Ther; 2022 Jan; 30(1):145-163. PubMed ID: 34418541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.